3 Results Found

Advanced Search

Select all

Results per page

Select all

Case Report

921 Views

7 Pages

Treatment of Leptomeningeal Disease with Tepotinib in a Patient with Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Presenting with Extensive Metastasis Involving Duodenum

Jacquelyn Shugarts,
Aida Amado,
Taylor Praska,
Monica Camou and
Jiaxin Niu

Reports2025, 8(2), 96;https://doi.org/10.3390/reports8020096

-

18 June 2025

Background and Clinical Significance: The mesenchymal–epithelial transition (MET) exon 14 skipping mutation (METex14) is a rare genetic alteration occurring in non-small cell lung cancer (NSCLC). Tyrosine kinase inhibitors (TKIs) are the approv...

Full Article

Article

12 Citations

2,998 Views

19 Pages

Heterogeneous Expression of PD-L1, B7x, B7-H3, and HHLA2 in Pulmonary Sarcomatoid Carcinoma and the Related Regulatory Signaling Pathways

Feng Wang,
Ayse Ece Cali Daylan,
Lei Deng,
Jihua Yang,
Janaki Sharma,
Christopher Su,
Shenduo Li,
Xingxing Zang,
Balazs Halmos and
Alain Borczuk
+ 1 author

Cancers2023, 15(13), 3372;https://doi.org/10.3390/cancers15133372

-

27 June 2023

Immunotherapy has transformed lung cancer management, but PSC remains an aggressive subtype with a poor prognosis. This study investigates the differential expression of PD-L1 and alternative immune checkpoints (ICs; B7x, B7-H3, and HHLA2), and genet...

Full Article

Review

12 Citations

6,077 Views

19 Pages

Landscape of Savolitinib Development for the Treatment of Non-Small Cell Lung Cancer with MET Alteration—A Narrative Review

Xiaokuan Zhu,
Yao Lu and
Shun Lu

Cancers2022, 14(24), 6122;https://doi.org/10.3390/cancers14246122

-

12 December 2022

Non-small cell lung cancer (NSCLC) is increasingly being treated with targeted therapies. Savolitinib (Orpathys®) is highly selective mesenchymal epithelial transition (MET)–tyrosine kinase inhibitor (TKI), which is conditionally approved i...

Full Article